A Phase 2 trial of RX-5902 and pembrolizumab in patients with metastatic triple negative breast cancer (mTNBC)
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2018
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; RX 5902 (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 06 Dec 2018 According to a Rexahn Pharmaceuticals media release, the date of first patient enrolment in this trial is changed from early 2019 to the second half of 2019.
- 20 Nov 2018 New trial record
- 05 Nov 2018 According to a Rexahn Pharmaceuticals media release, the company announced a clinical trial collaboration agreement with Merck for this trial.